Paysign (PAYS) Q2 2026 earnings review
Explosive Pharma Growth Drives Massive Operating Leverage
Paysign delivered a blowout Q2, raising full-year guidance across all metrics. The core story is a highly favorable mix shift: the higher-margin Patient Affordability (Pharma) segment grew 89% YoY, fundamentally transforming the company's profitability profile. While the legacy Plasma business continues to lose physical center count, increased throughput drove 21% YoY revenue growth. Driven by the Pharma surge, Adjusted EBITDA more than doubled YoY to $9.61M. The business has clearly reached an inflection point where incremental revenue drops cleanly to the bottom line.
🐂 Bull Case
The Patient Affordability segment is accelerating, adding 51 net programs in the last 12 months. This higher-margin revenue stream expanded consolidated gross margins to 63.3%.
Revenue grew 48% YoY, while operating expenses (excluding a one-time gain) grew only 15%. This structural leverage caused Adjusted EBITDA to surge 113% YoY.
🐻 Bear Case
The physical foundation of the Plasma business continues to erode, with total centers dropping to 561 from 607 a year ago due to customer closures and competitor transitions.
Pharma revenue decelerated sequentially ($14.65M in Q2 vs $15.68M in Q1) due to the exhaustion of Q1 deductible reset dynamics, creating lumpiness in sequential earnings.
⚖️ Verdict: 🟢
Bullish. The strategic pivot toward Patient Affordability is paying off spectacularly. The operating leverage is structural, not a one-time fluke, giving management the confidence to aggressively raise FY26 guidance.
Key Themes
Patient Affordability (Pharma) Segment Dominance
Accelerating. Pharma revenue grew 88.9% YoY to $14.65M. The company exited Q2 with 148 active programs (up from 135 in Q1). The proprietary 'Dynamic Business Rules' technology continues to differentiate the platform, driving 54% YoY growth in processed claims. This segment is now the undisputed primary growth engine.
Massive Operating Margin Expansion
Accelerating. Operating margin jumped from 7.5% in 25Q2 to 24.8% in 26Q2. Even stripping out a $990K non-cash gain from the Gamma acquisition contingent consideration, adjusted operating margin was an impressive 21.3%. The fixed-cost nature of the platform means that as Pharma mix increases, profits grow disproportionately faster than sales.
Plasma Yield Increases Despite Shrinking Footprint (Macro)
Stable. The broader plasma industry is normalizing after a multi-year inventory glut. Despite losing 46 centers YoY, Plasma revenue increased 21.4% to $13.04M. Average monthly revenue per center rose to $7,699 from $7,098 a year ago. Increased donor throughput and dollars loaded per remaining center are effectively offsetting physical footprint attrition.
Physical Plasma Center Attrition
While plasma revenue grew YoY, the underlying center count narrative contradicts the growth. Centers dropped from 607 in 25Q2 to 573 in 26Q1, and further to 561 in 26Q2. Management previously blamed 'garbage centers' and client transitions to competitors. Continual contraction of the physical network risks long-term ceiling limits on Plasma growth if throughput efficiency plateaus.
Pharma Revenue Seasonality
Pharma revenue decelerated sequentially, dropping to $14.65M in Q2 from $15.68M in Q1. This was expected, as management noted in Q1 that deductible resets cause Q1 to be the strongest quarter for patient affordability claims. However, investors must monitor this to ensure the sequential drop is purely seasonal and not indicative of slowing new program ramp-ups.
SaaS Platform (BECCS) FDA Timelines
The Gamma Innovation acquisition brought the Blood Establishment Computer System (BECCS) platform. Management has historically pitched this SaaS technology as a 'game changer' that transitions Paysign from a payments vendor to an integrated tech partner. However, there is still no revenue contribution, and it remains trapped in opaque FDA discussions.
Other KPIs
Accelerating. Up 113.0% YoY from $4.51M in 25Q2. Represents a robust 34% margin. Diluted Adjusted EBITDA per share doubled to $0.16. The massive flow-through highlights the scalability of the Pharma segment.
Stable. Up $6.31M during the first six months of 2026. The company maintains a pristine balance sheet with zero bank debt. This expanding war chest provides optionality for shareholder returns or further bolt-on M&A.
The company recorded a $990k non-cash benefit to SG&A expenses due to a fair value adjustment on contingent consideration related to the Gamma acquisition. Excluding this, operating expenses would have grown 15.1% YoY instead of the reported 5.5%.
Guidance
Accelerating. Management raised the full-year target from the prior $106.5M - $110.5M range. The $115.5M midpoint implies exceptional ~41% YoY growth, driven by sustained momentum in Pharma and better-than-expected throughput in Plasma.
Decelerating slightly. The guidance implies 32.0% - 38.9% YoY growth. While sequentially higher than Q2 ($28.25M), the YoY growth rate cools slightly from the 48-50% hyper-growth witnessed in Q1 and Q2, reflecting tougher comps in the back half of the year.
Accelerating. Raised significantly from the prior $30.0M - $33.0M guide. This implies an annual Adjusted EBITDA margin of over 31% at the midpoint, underscoring the permanent structural shift in profitability.
Accelerating. The company exited Q2 with 148 programs. Guiding for an exit of 165-170 in Q3 implies they expect to add roughly 17-22 net new programs in a single quarter, reflecting a massive and active sales pipeline.
Key Questions
Plasma Center Count Floor
The plasma center count has fallen to 561 despite strong revenue yields per center. At what point does the physical attrition outpace the throughput gains, and when do you expect the total center count to stabilize?
SaaS Platform (BECCS) FDA Timeline
Discussions with the FDA regarding the donor management system were mentioned heavily in previous quarters but omitted from the Q2 release. Are there specific regulatory hurdles delaying clearance, and has the timeline for revenue contribution been pushed to 2027?
Capital Allocation Strategy
With unrestricted cash cresting $27 million and structural free cash flow expanding rapidly, what is the primary lens for capital allocation? Is the priority M&A, accelerating software R&D, or returning capital to shareholders via buybacks?